Estela Prada Varela
Investigador post-doc
Research group
Research line:
Treatment of Pediatric Rabdomiosarcoma
The researcher has a degree in Pharmacy since 2014 from the University of Santiago de Compostela.
In 2015, she obtained a master's degree in Translational Biomedical Research from the Vall d'Hebron Research Institute - Universitat Autònoma de Barcelona.
In 2016 she joined as a predoctoral researcher in the Developmental Tumors laboratory of the Sant Joan de Déu Hospital of Dr. Jaume Mora for the development of new targets and pharmacological opportunities in the treatment of pediatric rhabdomyosarcoma.
In November 2021 she obtained her PhD from the University of Barcelona, with her doctoral thesis "Target therapy in Rhabdomyosarcoma: Discovering new targets and opportunities", supervised by Dr. Jaume Mora (SJD) and Dr. Inmaculada Hernandez (IMIM ).
She currently works as a postdoctoral researcher in the Sarcomas and Histiocytosis group, included in the IRSJD Pediatric Cancer program.
Professional network profiles
Last Publications
- Figuerola-Bou E, Rios-Astorch C, Blanco E, Sanchez-Jimenez M, Táboas-Outón P, Fernandez-Isern G, Gomez-Gonzalez S, Muñoz-Aznar O, Castellano P, Pérez-Jaume S, Prada-Varela E, Mateo-Lozano S, Riggi N, Avgustinova A, Lavarino C, Di Croce L, Sánchez-Molina S and Mora J KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma Biorxiv . : .
- García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment BMC Cancer . 22(1): 669-669.
- Alcon C, Martín F, Prada-Varela E, Mora J, Soriano A, Guillén G, Gallego S, Roma J, Samitier J, Villanueva A and Montero J MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment Cell Death Discovery . 8(1): 172-172.
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Caracterización y relevancia del entorno epigenético en el desarrollo del sarcoma de Ewing
- Leader
- Jaume Mora Graupera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI16/00245
- Starting - finishing date:
- 2017 - 2020
- Project name:
- Fundación Leo Messi_Convenio Rabdomiosarcoma
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fundación Privada Leo Messi
- Code
- PFNR0068
- Starting - finishing date:
- 2016 - 2019